Anti-p27 KIP 1 (phospho T187) antibody (ab75908)
Key features and details
- Rabbit polyclonal to p27 KIP 1 (phospho T187)
- Suitable for: WB, IHC-P
- Reacts with: Human
- Isotype: IgG
Overview
-
Product name
Anti-p27 KIP 1 (phospho T187) antibody
See all p27 KIP 1 primary antibodies -
Description
Rabbit polyclonal to p27 KIP 1 (phospho T187) -
Host species
Rabbit -
Tested applications
Suitable for: WB, IHC-Pmore details -
Species reactivity
Reacts with: Human -
Immunogen
Synthetic peptide corresponding to Human p27 KIP 1 (phospho T187) conjugated to keyhole limpet haemocyanin.
Database link: P46527 -
General notes
The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing this with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation. Please check that this product meets your needs before purchasing.
If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, along with publications, customer reviews and Q&As
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C. Stable for 12 months at -20°C. -
Storage buffer
pH: 7.40
Preservative: 0.02% Sodium azide
Constituents: 50% Glycerol, 0.87% Sodium chloride, PBS
PBS without Mg2+ and Ca2+ -
Concentration information loading...
-
Purity
Immunogen affinity purified -
Purification notes
ab75908 was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatography using non-phosphopeptide corresponding to the phosphorylation site. -
Clonality
Polyclonal -
Isotype
IgG -
Research areas
Associated products
-
Compatible Secondaries
-
Isotype control
-
Positive Controls
-
Recombinant Protein
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab75908 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
WB | (1) |
1/500 - 1/1000. Predicted molecular weight: 22 kDa.
|
IHC-P |
1/50 - 1/100.
|
Notes |
---|
WB
1/500 - 1/1000. Predicted molecular weight: 22 kDa. |
IHC-P
1/50 - 1/100. |
Target
-
Function
Important regulator of cell cycle progression. Involved in G1 arrest. Potent inhibitor of cyclin E- and cyclin A-CDK2 complexes. Forms a complex with cyclin type D-CDK4 complexes and is involved in the assembly, stability, and modulation of CCND1-CDK4 complex activation. Acts either as an inhibitor or an activator of cyclin type D-CDK4 complexes depending on its phosphorylation state and/or stoichometry. -
Tissue specificity
Expressed in all tissues tested. Highest levels in skeletal muscle, lowest in liver and kidney. -
Involvement in disease
Defects in CDKN1B are the cause of multiple endocrine neoplasia type 4 (MEN4) [MIM:610755]. Multiple endocrine neoplasia (MEN) syndromes are inherited cancer syndromes of the thyroid. MEN4 is a MEN-like syndrome with a phenotypic overlap of both MEN1 and MEN2. -
Sequence similarities
Belongs to the CDI family. -
Domain
A peptide sequence containing only AA 28-79 retains substantial Kip1 cyclin A/CDK2 inhibitory activity. -
Post-translational
modificationsPhosphorylated; phosphorylation occurs on serine, threonine and tyrosine residues. Phosphorylation on Ser-10 is the major site of phosphorylation in resting cells, takes place at the G(0)-G(1) phase and leads to protein stability. Phosphorylation on other sites is greatly enhanced by mitogens, growth factors, cMYC and in certain cancer cell lines. The phosphorylated form found in the cytoplasm is inactivate. Phosphorylation on Thr-198 is required for interaction with 14-3-3 proteins. Phosphorylation on Thr-187, by CDK2 leads to protein ubiquitination and proteasomal degradation. Tyrosine phosphorylation promotes this process. Phosphorylation by PKB/AKT1 can be suppressed by LY294002, an inhibitor of the catalytic subunit of PI3K. Phosphorylation on Tyr-88 and Tyr-89 has no effect on binding CDK2, but is required for binding CDK4. Dephosphorylated on tyrosine residues by G-CSF.
Ubiquitinated; in the cytoplasm by the KPC complex (composed of RNF123/KPC1 and UBAC1/KPC2) and, in the nucleus, by SCF(SKP2). The latter requires prior phosphorylation on Thr-187. Ubiquitinated; by a TRIM21-containing SCF(SKP2)-like complex; leads to its degradation.
Subject to degradation in the lysosome. Interaction with SNX6 promotes lysosomal degradation. -
Cellular localization
Nucleus. Cytoplasm. Endosome. Nuclear and cytoplasmic in quiescent cells. AKT-or RSK-mediated phosphorylation on Thr-198, binds 14-3-3, translocates to the cytoplasm and promotes cell cycle progression. Mitogen-activated UHMK1 phosphorylation on Ser-10 also results in translocation to the cytoplasm and cell cycle progression. Phosphorylation on Ser-10 facilitates nuclear export. Translocates to the nucleus on phosphorylation of Tyr-88 and Tyr-89. Colocalizes at the endosome with SNX6 and this leads to lysosomal degradation. - Information by UniProt
-
Database links
- Entrez Gene: 1027 Human
- Omim: 600778 Human
- SwissProt: P46527 Human
- Unigene: 238990 Human
-
Alternative names
- AA408329 antibody
- AI843786 antibody
- Cdki1b antibody
see all
Images
-
All lanes : Anti-p27 KIP 1 (phospho T187) antibody (ab75908) at 1/500 dilution
Lane 1 : Extracts from HeLa cells treated with EGF with immunising peptide
Lane 2 : Extracts from HeLa cells treated with EGF
Lane 3 : Extracts from HeLa cells treated with IFN alpha
Predicted band size: 22 kDa
Observed band size: 27 kDa why is the actual band size different from the predicted? -
Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using ab75908 (left) at 1/50 dilution or the same antibody preincubated with blocking peptide (right).
Protocols
Datasheets and documents
-
SDS download
-
Datasheet download
References (12)
ab75908 has been referenced in 12 publications.
- Chen Q et al. miR-30a-3p inhibits the proliferation of liver cancer cells by targeting DNMT3a through the PI3K/AKT signaling pathway. Oncol Lett 19:606-614 (2020). PubMed: 31897176
- Wu HK et al. PHLPP2 is regulated by competing endogenous RNA network in pathogenesis of colon cancer. Aging (Albany NY) 12:12812-12840 (2020). PubMed: 32633726
- Ren G et al. Reduced Basal Nitric Oxide Production Induces Precancerous Mammary Lesions via ERBB2 and TGFß. Sci Rep 9:6688 (2019). PubMed: 31040372
- Walter DM et al. RB constrains lineage fidelity and multiple stages of tumour progression and metastasis. Nature 569:423-427 (2019). PubMed: 31043741
- Ale-Agha N et al. CDKN1B/p27 is localized in mitochondria and improves respiration-dependent processes in the cardiovascular system-New mode of action for caffeine. PLoS Biol 16:e2004408 (2018). PubMed: 29927970